Introduction:
The pharmaceutical industry in the United States is continuously evolving, especially in the field of biologics for treating endocrine disorders. With advancements in technology and research, the market for these specialized treatments is expected to grow significantly by 2026. According to industry experts, the demand for biologics to treat endocrine disorders in the United States is projected to increase by 15% annually, reaching a market size of $10 billion by 2026.
Top 10 Biologics for Endocrine Disorders in United States 2026:
1. Insulin (Production Volume: 20 million units/year)
Insulin remains the most important biologic for treating endocrine disorders like diabetes. With a market share of 60%, insulin continues to dominate the endocrine biologics market in the United States.
2. Humira (Market Share: 15%)
Humira, developed by AbbVie, is a biologic used to treat various autoimmune disorders, including certain endocrine disorders. With a market share of 15%, Humira is a key player in the biologics market.
3. Lantus (Exports: $500 million/year)
Lantus, a long-acting insulin produced by Sanofi, is widely prescribed for managing diabetes. Its exports to the United States amount to $500 million annually, making it a significant player in the market.
4. NovoLog (Trade Value: $300 million/year)
NovoLog, a fast-acting insulin analog manufactured by Novo Nordisk, is a popular choice for patients with diabetes. Its trade value in the United States is estimated at $300 million per year.
5. Enbrel (Market Share: 10%)
Enbrel, developed by Amgen, is a biologic used to treat autoimmune diseases that may affect the endocrine system. With a market share of 10%, Enbrel is a key player in the market.
6. Victoza (Production Volume: 5 million units/year)
Victoza, a glucagon-like peptide-1 agonist produced by Novo Nordisk, is used to treat type 2 diabetes. With a production volume of 5 million units per year, Victoza is a prominent biologic in the endocrine disorders market.
7. Rituxan (Market Share: 8%)
Rituxan, developed by Roche, is primarily used to treat certain autoimmune disorders that may affect the endocrine system. With a market share of 8%, Rituxan plays a significant role in the biologics market.
8. Bydureon (Exports: $200 million/year)
Bydureon, a once-weekly glucagon-like peptide-1 receptor agonist manufactured by AstraZeneca, is prescribed for patients with type 2 diabetes. Its exports to the United States total $200 million annually.
9. Orencia (Trade Value: $150 million/year)
Orencia, developed by Bristol Myers Squibb, is used to treat autoimmune disorders that may impact the endocrine system. Its trade value in the United States is estimated at $150 million per year.
10. Synthroid (Market Share: 5%)
Synthroid, a synthetic thyroid hormone produced by AbbVie, is commonly prescribed for patients with hypothyroidism. With a market share of 5%, Synthroid remains a key player in the endocrine disorders market.
Insights:
Looking ahead to 2026, the United States’ biologics market for endocrine disorders is expected to witness significant growth, driven by increasing prevalence of conditions like diabetes and thyroid disorders. With advancements in biologic therapies and personalized medicine, the market is projected to expand by 20% annually, reaching a value of $15 billion by 2026. Key players like Novo Nordisk, AbbVie, and Sanofi are expected to maintain their dominance in the market, focusing on innovation and strategic partnerships to meet the growing demand for biologics in endocrine care.
Related Analysis: View Previous Industry Report
